Treatment Information

Back

Bladder Cancer treatment details. Chemotherapy.

San Camillo and Forlanini Hospitals , Rome, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:5City/State/Province:Rome
Treatments:ChemotherapyHospital:San Camillo and Forlanini Hospitals
Drugs:Journal:Link
Date:Jan 2015

Description:

Patients:
This phase 3 study involved patients with muscle-invasive urothelial carcinoma of the bladder who had previous radical cystectomy surgery. Patients were divided into two separate treatment groups. Group A consisted of 141 patients with a median age of 61 years, and 79% were male. Group B consisted of 143 patients with a median age of 61 years, and 80% were male.

Treatment:
Patients in group A received chemotherapy with gemcitabine, cisplatin, methotrexate, vinblastine, and doxorubicin immediately after their surgery.

Patients in group B received deferred chemotherapy with gemcitabine, cisplatin, methotrexate, vinblastine, and doxorubicin at the time of cancer relapse following surgery.

Toxicities:
There was one treatment-related death due to sepsis (infection) in group A. Grade 4 neutropenia and low platelet counts were also reported.

There was one treatment-related death due to unknown causes in group B. Grade 4 neutropenia, low platelet count, and liver toxicity were also reported.

Results:
The median overall survival times for groups A and B were 80.88 and 55.2 months, respectively.

Support:
This study was partially supported by the Eli Lilly pharmaceutical company.

Correspondence: Dr. Cora N Sternberg; email: cstern@mclink.it



Back